BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price upped by stock analysts at JPMorgan Chase & Co. from $12.00 to $13.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 55.00% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Weiss Ratings cut shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 29th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Finally, Wedbush cut their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded up $0.12 during trading on Wednesday, hitting $8.39. The company’s stock had a trading volume of 9,559,254 shares, compared to its average volume of 4,858,194. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.22. The company has a market cap of $2.14 billion, a PE ratio of -5.58 and a beta of 0.57. The business’s 50 day simple moving average is $9.31 and its 200-day simple moving average is $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals’s revenue was up 33.6% on a year-over-year basis. During the same period last year, the firm posted $0.15 EPS. Analysts expect that BioCryst Pharmaceuticals will post -2.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BCRX. BlackRock Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $238,930,000. Jupiter Topco LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $95,268,000. Janus Henderson Group PLC boosted its holdings in BioCryst Pharmaceuticals by 20.3% during the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after buying an additional 1,504,120 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after buying an additional 4,271,504 shares in the last quarter. Finally, Bank of America Corp DE grew its position in BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after buying an additional 3,556,208 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.

BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.